Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its first quarter 2021 financial results on May 4, 2021. A conference call to discuss these results and provide corporate updates will follow at 4:30 PM ET on the same day. Interested parties can join the call via toll-free or international numbers and access the live webcast on the Company’s investor relations page. Deciphera specializes in innovative cancer treatments, including QINLOCK®, its FDA-approved therapy for fourth-line gastrointestinal stromal tumors.
- Deciphera continues to advance multiple product candidates in clinical studies.
- QINLOCK® is FDA-approved for fourth-line gastrointestinal stromal tumors.
- None.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021.
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, May 4, 2021, to discuss the Company’s financial results and provide a corporate update.
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 5470938. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005402/en/
FAQ
When will Deciphera Pharmaceuticals report its Q1 2021 financial results?
What time is Deciphera Pharmaceuticals' conference call on May 4, 2021?
How can I access the webcast for Deciphera's earnings call?
What is QINLOCK® used for?
